{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:11:55Z","timestamp":1782537115263,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11307-022-01735-z","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T01:02:46Z","timestamp":1657155766000},"page":"862-873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"24","author":[{"given":"Cyrille","family":"Sur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Adamczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Sampat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Suhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-7874","authenticated-orcid":false,"given":"Idriss","family":"Bennacef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"1735_CR1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256:184\u2013185","journal-title":"Science"},{"key":"1735_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/NEN.0b013e3181919a48","volume":"68","author":"PT Nelson","year":"2009","unstructured":"Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 68:1\u201314","journal-title":"J Neuropathol Exp Neurol"},{"key":"1735_CR3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 8:595\u2013608","journal-title":"EMBO Mol Med"},{"key":"1735_CR4","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.3390\/ijms19123702","volume":"19","author":"GD Femminella","year":"2018","unstructured":"Femminella GD, Thayanandan T, Calsolaro V et al (2018) Imaging and molecular mechanisms of Alzheimer\u2019s disease: a review. Int J Mol Sci 19:3702","journal-title":"Int J Mol Sci"},{"key":"1735_CR5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.nicl.2013.03.014","volume":"2","author":"R Vandenberghe","year":"2013","unstructured":"Vandenberghe R, Adamczuk K, Dupont P, Laere KV, Ch\u00e9telat G (2013) Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer\u2019s disease. Neuroimage Clin 2:497\u2013511","journal-title":"Neuroimage Clin"},{"key":"1735_CR6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol 55:306\u2013319","journal-title":"Ann Neurol"},{"key":"1735_CR7","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","volume":"50","author":"N Nelissen","year":"2009","unstructured":"Nelissen N, Van Laere K, Thurfjell L et al (2009) Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 50:1251\u20131259","journal-title":"J Nucl Med"},{"key":"1735_CR8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A et al (2010) 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 68:319\u2013329","journal-title":"Ann Neurol"},{"key":"1735_CR9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00259-015-3156-9","volume":"43","author":"K Adamczuk","year":"2016","unstructured":"Adamczuk K, Schaeverbeke J, Nelissen N et al (2016) Amyloid imaging in cognitively normal older adults: comparison between (18)F-flutemetamol and (11)C-Pittsburgh compound B. Eur J Nucl Med Mol Imaging 43:142\u2013151","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1735_CR10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.nicl.2015.10.007","volume":"9","author":"JM Mountz","year":"2015","unstructured":"Mountz JM, Laymon CM, Cohen AD et al (2015) Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer\u2019s subjects. Neuroimage Clin 9:592\u2013598","journal-title":"Neuroimage Clin"},{"key":"1735_CR11","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2967\/jnumed.114.142109","volume":"55","author":"L Thurfjell","year":"2014","unstructured":"Thurfjell L, Lilja J, Lundqvist R et al (2014) Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med 55:1623\u20131628","journal-title":"J Nucl Med"},{"key":"1735_CR12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/WAD.0000000000000293","volume":"33","author":"K Duff","year":"2019","unstructured":"Duff K, Horn KP, Hoffman JM (2019) Long-term changes in 18F-flutemetamol uptake in nondemented older adults. Alzheimer Dis Assoc Disord 33:113\u2013117","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1735_CR13","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791\u20131800","journal-title":"Neurology"},{"key":"1735_CR14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00401-018-1897-9","volume":"136","author":"DR Thal","year":"2018","unstructured":"Thal DR, Beach TG, Zanette M et al (2018) Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid \u03b2-protein deposition. Acta Neuropathol 136:557\u2013567","journal-title":"Acta Neuropathol"},{"key":"1735_CR15","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s00259-021-05311-5","volume":"48","author":"M Bucci","year":"2021","unstructured":"Bucci M, Savitcheva I, Farrar G et al (2021) A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [(18)F]flutemetamol amyloid PET images. Eur J Nucl Med Mol Imaging 48:2183\u20132199","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1735_CR16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2967\/jnumed.114.149732","volume":"56","author":"K Chen","year":"2015","unstructured":"Chen K, Roontiva A, Thiyyagura P et al (2015) Improved power for characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med 56:560\u2013566","journal-title":"J Nucl Med"},{"key":"1735_CR17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3233\/JAD-180749","volume":"67","author":"CG Schwarz","year":"2019","unstructured":"Schwarz CG, Gunter JL, Lowe VJ et al (2019) A comparison of partial volume correction techniques for measuring change in serial amyloid PET SUVR. J Alzheimers Dis 67:181\u2013195","journal-title":"J Alzheimers Dis"},{"key":"1735_CR18","doi-asserted-by":"crossref","first-page":"13035","DOI":"10.1038\/s41598-017-13339-7","volume":"7","author":"J Yang","year":"2017","unstructured":"Yang J, Hu C, Guo N et al (2017) Partial volume correction for PET quantification and its impact on brain network in Alzheimer\u2019s disease. Sci Rep 7:13035","journal-title":"Sci Rep"},{"key":"1735_CR19","first-page":"2053","volume":"40","author":"CC Meltzer","year":"1999","unstructured":"Meltzer CC, Kinahan PE, Greer PJ et al (1999) Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 40:2053\u20132065","journal-title":"J Nucl Med"},{"key":"1735_CR20","first-page":"904","volume":"39","author":"OG Rousset","year":"1998","unstructured":"Rousset OG, Ma Y, Evans AC (1998) Correction for partial volume effects in PET: principle and validation. J Nucl Med 39:904\u2013911","journal-title":"J Nucl Med"},{"key":"1735_CR21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/B978-012161340-2\/50011-1","volume-title":"Quantitative functional brain imaging with positron emission tomography","author":"C Labb\u00e9","year":"1998","unstructured":"Labb\u00e9 C, Koepp M, Ashburner J, Spinks T, Richardson M, Duncan J, Cunningham V (1998) Absolute PET Quantification with Correction for Partial Volume Effects with Cerebral Structures. In: Carson RE, Daube-Witherspoon ME, Herscovitch P (eds) Quantitative functional brain imaging with positron emission tomography. Academic Press, San Diego, pp 59\u201366"},{"key":"1735_CR22","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1088\/0031-9155\/57\/21\/7101","volume":"57","author":"M Sattarivand","year":"2012","unstructured":"Sattarivand M, Kusano M, Poon I, Caldwell C (2012) Symmetric geometric transfer matrix partial volume correction for PET imaging: principle, validation and robustness. Phys Med Biol 57:7101\u20137116","journal-title":"Phys Med Biol"},{"key":"1735_CR23","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1523\/JNEUROSCI.23-03-00994.2003","volume":"23","author":"PM Thompson","year":"2003","unstructured":"Thompson PM, Hayashi KM, de Zubicaray G et al (2003) Dynamics of gray matter loss in Alzheimer\u2019s disease. J Neurosci 23:994\u20131005","journal-title":"J Neurosci"},{"key":"1735_CR24","doi-asserted-by":"publisher","unstructured":"Blinkouskaya Y, Weickenmeier J (2021) Brain Shape Changes Associated with Cerebral Atrophy in Healthy Aging and Alzheimer's Disease. Front Mech Eng. https:\/\/doi.org\/10.3389\/fmech.2021.705653","DOI":"10.3389\/fmech.2021.705653"},{"key":"1735_CR25","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.1021\/acs.jmedchem.6b00307","volume":"59","author":"JD Scott","year":"2016","unstructured":"Scott JD, Li SW, Brunskill AP et al (2016) Discovery of the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative verubecestat (MK-8931)-a \u03b2-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer\u2019s Disease. J Med Chem 59:10435\u201310450","journal-title":"J Med Chem"},{"key":"1735_CR26","doi-asserted-by":"crossref","unstructured":"Kennedy ME, Stamford AW, Chen X et al (2016) The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer's disease patients. Sci Transl Med 8:363ra150","DOI":"10.1126\/scitranslmed.aad9704"},{"key":"1735_CR27","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/cts.12645","volume":"12","author":"M Forman","year":"2019","unstructured":"Forman M, Palcza J, Tseng J et al (2019) Safety, tolerability, and pharmacokinetics of the beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor verubecestat (MK-8931) in healthy elderly male and female subjects. Clin Transl Sci 12:545\u2013555","journal-title":"Clin Transl Sci"},{"key":"1735_CR28","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cpt.1258","volume":"105","author":"KC Min","year":"2019","unstructured":"Min KC, Dockendorf MF, Palcza J et al (2019) Pharmacokinetics and pharmacodynamics of the BACE1 inhibitor verubecestat (MK-8931) in healthy Japanese adults: a randomized, placebo-controlled study. Clin Pharmacol Ther 105:1234\u20131243","journal-title":"Clin Pharmacol Ther"},{"key":"1735_CR29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13195-014-0089-7","volume":"6","author":"R Vassar","year":"2014","unstructured":"Vassar R (2014) BACE1 inhibitor drugs in clinical trials for Alzheimer\u2019s disease. Alzheimers Res Ther 6:89","journal-title":"Alzheimers Res Ther"},{"key":"1735_CR30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","volume":"286","author":"R Vassar","year":"1999","unstructured":"Vassar R, Bennett BD, Babu-Khan S et al (1999) Beta-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735\u2013741","journal-title":"Science"},{"key":"1735_CR31","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","volume":"378","author":"MF Egan","year":"2018","unstructured":"Egan MF, Kost J, Tariot PN et al (2018) Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 378:1691\u20131703","journal-title":"N Engl J Med"},{"key":"1735_CR32","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/brain\/awaa332","volume":"143","author":"C Sur","year":"2020","unstructured":"Sur C, Kost J, Scott D et al (2020) BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer\u2019s disease brain. Brain 143:3816\u20133826","journal-title":"Brain"},{"key":"1735_CR33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00259-014-2753-3","volume":"41","author":"SM Landau","year":"2014","unstructured":"Landau SM, Thomas BA, Thurfjell L, the Alzheimer\u2019s Disease Neuroimaging Intiative, et al (2014) Amyloid PET imaging in Alzheimer\u2019s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 41:398\u20131407","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1735_CR34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1006\/nimg.2001.0978","volume":"15","author":"N Tzourio-Mazoyer","year":"2002","unstructured":"Tzourio-Mazoyer N, Landeau B, Papathanassiou D et al (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273\u2013289","journal-title":"Neuroimage"},{"key":"1735_CR35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.neuroimage.2013.12.021","volume":"92","author":"DN Greve","year":"2014","unstructured":"Greve DN, Svarer C, Fisher PM et al (2014) Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage 92:225\u2013236","journal-title":"Neuroimage"},{"key":"1735_CR36","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.neuroimage.2016.02.042","volume":"132","author":"DN Greve","year":"2016","unstructured":"Greve DN, Salat DH, Bowen SL et al (2016) Different partial volume correction methods lead to different conclusions: An (18)F-FDG-PET study of aging. Neuroimage 132:334\u2013343","journal-title":"Neuroimage"},{"key":"1735_CR37","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3233\/JAD-170582","volume":"62","author":"LF Kalheim","year":"2018","unstructured":"Kalheim LF, Fladby T, Coello C, Bj\u00f8rnerud A, Selnes P (2018) [18F]-Flutemetamol uptake in cortex and white matter: comparison with cerebrospinal fluid biomarkers and [18F]-fludeoxyglucose. J Alzheimers Dis 62:1595\u20131607","journal-title":"J Alzheimers Dis"},{"key":"1735_CR38","first-page":"515","volume":"5","author":"K Heurling","year":"2015","unstructured":"Heurling K, Buckley C, Vandenberghe R, Laere KV, Lubberink M (2015) Separation of \u03b2-amyloid binding and white matter uptake of (18)F-flutemetamol using spectral analysis. Am J Nucl Med Mol Imaging 5:515\u2013526","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"1735_CR39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nicl.2017.08.011","volume":"16","author":"VJ Lowe","year":"2017","unstructured":"Lowe VJ, Lundt E, Knopman D et al (2017) Comparison of [18F]flutemetamol and [11C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer\u2019s disease dementia individuals. NeuroImage Clinical 16:295\u2013302","journal-title":"NeuroImage Clinical"},{"key":"1735_CR40","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jalz.2017.02.009","volume":"13","author":"AS Fleisher","year":"2017","unstructured":"Fleisher AS, Joshi AD, Sundell KL et al (2017) Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. Alzheimers Dement 13:1117\u20131124","journal-title":"Alzheimers Dement"},{"key":"1735_CR41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2967\/jnumed.118.209130","volume":"60","author":"P Chiao","year":"2019","unstructured":"Chiao P, Bedell BJ, Avants B et al (2019) Impact of reference and target region selection on amyloid PET SUV ratios in the phase 1b PRIME study of aducanumab. J Nucl Med 60:100\u2013106","journal-title":"J Nucl Med"},{"key":"1735_CR42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","volume":"10","author":"S Salloway","year":"2018","unstructured":"Salloway S, Honigberg LA, Cho W et al (2018) Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE). Alzheimers Res Ther 10:96","journal-title":"Alzheimers Res Ther"},{"key":"1735_CR43","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s00259-011-1745-9","volume":"38","author":"BA Thomas","year":"2011","unstructured":"Thomas BA, Erlandsson K, Modat M et al (2011) The importance of appropriate partial volume correction for PET quantification in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging 38:1104\u20131119","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1735_CR44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuroimage.2016.08.056","volume":"144","author":"CG Schwarz","year":"2017","unstructured":"Schwarz CG, Senjem ML, Gunter JL et al (2017) Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. Neuroimage 144:113\u2013127","journal-title":"Neuroimage"},{"key":"1735_CR45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.22248","volume":"69","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Pike KE, Ch\u00e9telat G et al (2011) Longitudinal assessment of A\u03b2 and cognition in aging and Alzheimer disease. Ann Neurol 69:181\u2013192","journal-title":"Ann Neurol"},{"key":"1735_CR46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN et al (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363\u2013372","journal-title":"Lancet Neurol"},{"key":"1735_CR47","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C et al (2021) Donanemab in Early Alzheimer\u2019s Disease. N Engl J Med 384:1691\u20131704","journal-title":"N Engl J Med"},{"key":"1735_CR48","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamaneurol.2018.0894","volume":"75","author":"DA Wolk","year":"2018","unstructured":"Wolk DA, Sadowsky C, Safirstein B et al (2018) Use of flutemetamol F18-labeled positron emission tomography and other biomarkers to assess risk of clinical progression in patients with amnestic mild cognitive impairment. JAMA Neurol 75:1114\u20131123","journal-title":"JAMA Neurol"},{"key":"1735_CR49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fnagi.2019.00251","volume":"11","author":"S Hatashita","year":"2019","unstructured":"Hatashita S, Wakebe D, Kikuchi Y, Ichijo A (2019) Longitudinal assessment of amyloid-\u03b2 deposition by [18F]-flutemetamol PET imaging compared with [11C]-PIB across the spectrum of Alzheimer\u2019s disease. Front Aging Neurosci 11:251","journal-title":"Front Aging Neurosci"},{"key":"1735_CR50","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaneurol.2019.2214","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O (2019) Staging \u03b2-amyloid pathology with amyloid positron emission tomography. JAMA Neurol 76:1319\u20131329","journal-title":"JAMA Neurol"},{"key":"1735_CR51","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.nicl.2016.05.017","volume":"11","author":"CG Schwarz","year":"2016","unstructured":"Schwarz CG, Gunter JL, Wiste HJ et al (2016) A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer\u2019s disease severity. Neuroimage Clin 11:802\u2013812","journal-title":"Neuroimage Clin"},{"issue":"1\u201315","key":"1735_CR52","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC et al (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11(1\u201315):e1-4","journal-title":"Alzheimers Dement"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-022-01735-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T01:38:38Z","timestamp":1669167518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-022-01735-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1735"],"URL":"https:\/\/doi.org\/10.1007\/s11307-022-01735-z","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"13 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"CS, JK, IB, and MFE are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, & may own stock and\/or stock options in Merck and Co., Inc., Rahway, NJ, USA.KA, DS, MS, and JS are employees of Clario,\u00a0San Mateo,\u00a0CA, USA.CB, GF, and BN are employees of GE Healthcare, Amersham, UK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}]}}